IONS Bepirovirsen Oct 26 PDUFA: 19% HBV Functional Cure

GSK closed at $52.07 with a $106.6 billion market cap. Ionis Pharmaceuticals closed at $53.28 with an $8.9 billion market cap. On October 26, 2026, the FDA will decide on bepirovirsen, the first antisense therapy to achieve clinically meaningful functional cure rates in chronic hepatitis B. The drug is licensed by GSK from Ionis, and the economics split tells you where the investable thesis lives. GSK at $106.6B will not move on this approval. Ionis at $8.9B will.

The disease context is why 19% matters. Chronic hepatitis B affects 250 million people worldwide and 1.7 million in the United States. It accounts for 56% of liver cancer cases globally. The current standard of care is nucleos(t)ide analogue therapy, which suppresses viral replication but requires lifelong daily dosing. The functional cure rate with standard of care is under 1%. A functional cure means hepatitis B surface antigen (HBsAg) and HBV DNA are undetectable in blood for at least 24 weeks after stopping all treatment. Patients who achieve it can stop medication, avoid lifelong side effects, and see a dramatic reduction in liver cancer risk. Today, almost nobody gets there.

Bepirovirsen changes that. The B-Well 1 and B-Well 2 Phase 3 trials, published in the New England Journal of Medicine, enrolled 1,838 patients across 29 countries with noncirrhotic chronic HBV on stable NA therapy and HBsAg levels between 100 and 3,000 IU/mL. Patients were randomized 2:1 to receive 300 mg subcutaneous bepirovirsen weekly for 24 weeks or placebo. The primary endpoint was functional cure at week 72.

The results were statistically significant in both trials. In B-Well 1, 20% of bepirovirsen patients (127 of 650) achieved functional cure versus 0% of placebo (0 of 328, p<0.001). In B-Well 2, 19% (106 of 570) achieved functional cure versus 0% of placebo (0 of 286, p<0.001). Zero percent in the placebo arm is the number that matters. Standard of care alone cured nobody. Bepirovirsen cured nearly one in five.

The subgroup data is where the FDA will focus its label decision. Among patients with baseline HBsAg at or below 1,000 IU/mL, a group representing approximately 45% of diagnosed CHB cases, the functional cure rate jumped to 26% (200 of 768 versus 0 of 393 placebo, p<0.001). Among patients with HBsAg between 1,000 and 3,000 IU/mL, the cure rate fell to 5-10%. This is not a subtle difference. The drug works dramatically better in patients with lower viral antigen levels. GSK and Ionis are banking on the FDA approving the broader HBsAg at or below 3,000 population, but the FDA could narrow the label to the at or below 1,000 subgroup where the cure rate is 26% versus 5-10% at higher baseline HBsAg. A narrowed label cuts the addressable population roughly in half but does not change the fundamental clinical story. This is the key regulatory risk, and it is a label risk, not an approval risk. The Breakthrough Therapy designation and Priority Review both signal the FDA sees the benefit (ClinicalTrials.gov NCT05630807, NCT05630820).

The safety signal is the second FDA concern. Grade 3 or higher adverse events occurred in 16% of bepirovirsen patients versus 3% of placebo. The most common Grade 3 event was alanine aminotransferase (ALT) elevation, seen in 6% of patients. ALT elevation in a hepatitis B drug is a liver enzyme signal the FDA takes seriously, because the drug treats a liver disease. The clinical interpretation is that ALT flares may represent immune reactivation as HBsAg declines, which is mechanistically plausible and a sign the drug is working, not failing. The Phase 2b B-Clear study, which preceded the Phase 3 program, showed that patients with ALT flares during treatment had higher rates of HBsAg loss, supporting the immune reactivation hypothesis. But the FDA will require post-marketing monitoring regardless, and the label will likely include a boxed warning or enhanced surveillance for hepatic events. Serious adverse events were 7% versus 4% for placebo. No deaths were attributed to the drug.

The durability question is the third FDA concern. The B-Well trials measured functional cure at week 72, which is 24 weeks after stopping all treatment including NA therapy. The NEJM editorial by Anna Lok noted that the durability of HBsAg loss must be confirmed with longer follow-up, and that alternative therapies are needed for patients with cirrhosis or baseline HBsAg above 3,000 IU/mL. The trial excluded cirrhotic patients, who represent a significant fraction of the CHB population and carry the highest risk of hepatocellular carcinoma. A label that covers only noncirrhotic, low-HBsAg patients will leave the highest-risk patients untreated. GSK will need post-approval data in cirrhotic patients to expand the label, which is a multi-year process. This limits the near-term addressable market but does not change the approval calculus for October 26.

The competitive picture is thin. There are no approved functional cure therapies for chronic hepatitis B. Gilead’s lenacapavir dominates HIV prevention and treatment in the broader infectious disease space, as we covered in our lenacapavir PrEP analysis, but it targets a different virus entirely. Interferon-based regimens achieve functional cure in 3-7% of patients but with significant toxicity and poor tolerability. Bepirovirsen at 19% is not an incremental improvement over interferon. It is a different category of outcome. For a sector where functional cure was considered nearly impossible, 19% is the first data point that makes commercialization of a finite-duration HBV therapy realistic. Our infectious disease catalysts roundup flagged bepirovirsen as the highest-impact ID catalyst of 2026, and the Phase 3 data confirms why.

The valuation split is where the investable thesis diverges from the clinical thesis. GSK models peak sales above £2 billion ($2.7 billion) for bepirovirsen. At $2.7 billion in peak revenue against a $106.6 billion market cap, bepirovirsen represents 2.5% of GSK’s valuation at full penetration. GSK’s Q1 2026 revenue was £9.4 billion across its entire portfolio. Bepirovirsen is meaningful to GSK’s 2031 growth target of £40 billion in annual revenue, but it will not move the stock on October 26. The same cannot be said for Ionis.

Ionis earns tiered royalties of 10-12% on bepirovirsen sales. At $2.7 billion peak revenue, that is approximately $270 to $324 million in annual royalty income for a company with $246 million in Q1 2026 total revenue. Bepirovirsen alone could add more than 25% to Ionis’s top line at peak, and it is not even Ionis’s lead asset. Ionis also has zilganersen (Alexander disease) with a PDUFA on September 22, where our zilganersen platform analysis laid out the full thesis. Two PDUFAs in 35 days. If both approve, Ionis transitions from a single-product revenue base to a multi-asset platform with two commercial drugs and a deep pipeline behind them. We covered the Q2 earnings and pipeline updates in our Ionis earnings analysis.

The comp that frames the IONS opportunity is Alnylam, the RNAi platform leader. Alnylam trades at $37 billion versus Ionis at $8.9 billion, a 4.2x market cap gap. Both trade at comparable P/S ratios in the 8-9x range. The market is not discounting Ionis’s platform quality. It is applying a similar multiple to a smaller revenue base. Every approval narrows that revenue gap. Bepirovirsen at 10-12% royalties on $2.7 billion in peak sales is one narrowing event. Zilganersen is another. The platform thesis is that Ionis does not need multiple expansion to double. It needs revenue growth, and two PDUFAs in 35 days is the fastest path to that growth we have seen in the RNA therapeutics space.

For GSK, the verdict is straightforward: hold. Approval is likely given the Breakthrough Therapy designation and statistically significant Phase 3 data across all ranked endpoints. The stock will not move. Bepirovirsen at $2.7 billion peak is 2.5% of GSK’s market cap. Investors looking for GSK exposure should read our GSK Q2 earnings analysis, where the thesis is cost savings and pipeline breadth, not a single drug approval. For a PDUFA primer on how these dates work, the mechanics are simple: October 26 is the goal date, and the FDA can act early.

For Ionis, the verdict is buy ahead of the September 22 zilganersen PDUFA and scale in through October 26. Two binary events in 35 days is high volatility, so position size accordingly. The worst case is one approval and one complete response letter, which still leaves Ionis with a validated platform and a deep pipeline. The best case is two approvals, two new revenue streams, and a market cap that starts closing the gap with Alnylam. At $53.28, IONS is pricing in neither approval. That is the bet.